Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Playtech raises expectations after strong B2B trading

(Sharecast News) - Playtech said on Friday that it now expects to report adjusted EBITDA of at least €90mi for the first half of 2025, after stronger-than-expected trading in its B2B segment and a boost from associate income, particularly from its Mexican joint venture Caliente Interactive. In a trading update ahead of its interim results in September, the FTSE 250 gambling technology group said Caliente had delivered a better-than-expected performance during the second quarter, benefitting from favourable sporting results.

The business also declared and paid its first dividend under a revised strategic agreement.

It added that it continued to see strong momentum across its B2B division, underpinning its confidence in a strategy focused on becoming a predominantly pure-play B2B business.

"Given the exciting growth opportunities ahead, the board remains very confident in Playtech's ability to execute on its strategy," the company said.

Playtech reiterated plans to step up investment in the US and Brazil in the second half, but said it remained cautious on regulatory headwinds in Brazil and Colombia, which were previously highlighted in its May update.

The group said it would publish its half-year results on 11 September.

At 0906 BST, shares in Playtech were up 0.63% at 400.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.